Nebula Research & Development LLC Xenon Pharmaceuticals Inc. Transaction History

Nebula Research & Development LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	BUY	$28.23 - $38.37 $385,678 - $524,210	13,662 Added 29.34%	60,223 $1.88 Billion
Q1 2025 May 15, 2025	BUY	$33.55 - $40.74 $879,043 - $1.07 Million	26,201 Added 128.69%	46,561 $1.56 Billion
Q4 2024 Feb 14, 2025	SELL	$38.14 - $45.74 $148,936 - $178,614	-3,905 Reduced 16.09%	20,360 $798 Million
Q3 2024 Nov 14, 2024	SELL	$36.12 - $43.96 $214,227 - $260,726	-5,931 Reduced 19.64%	24,265 $955 Million
Q2 2024 Aug 14, 2024	BUY	$36.25 - $43.75 $1.09 Million - $1.32 Million	30,196 New	30,196 $1.18 Billion
Q4 2023 Feb 14, 2024	BUY	$28.7 - $46.46 $208,964 - $338,275	7,281 New	7,281 $335 Million

242

74M

235K

302K

Ticker XENE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,263,500
Market Cap $2.54B
Description
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopath...

Get notified when there are updates to the investment portfolio of Nebula Research & Development LLC, based on Form 13F filings with the SEC.

Stay updated on Nebula Research & Development LLC with notifications on news.